• phosphoinositide 3-kinase (PI3K) inhibitor
• alpelisib based treatment
• alpelisib plus letrozole
• buparlisib based treatment
• buparlisib plus letrozole

• versus all
• vs endocrine therapy
• vs letrozole

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only